Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | ACHE | P22303 | 1/20 | 0.60 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.55 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.55 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.51 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | TDO2 | P48775 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.49 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | PLK1 | P53350 | 2/20 | 0.47 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CTSD | P07339 | 1/20 | 0.46 |
| ▸ | HCN1 | O60741 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19531891 | 0.86 | IRAK4 (0.64) | IRAK4ALDH1A1ACHEKCNK3KCNK9 | |
| SCHEMBL1655461 | 0.84 | SMN1; SMN2 (0.56) | ALDH1A1KAT2BBAZ2BGAAKDM4E | |
| SCHEMBL2104535 | 0.84 | IRAK4 (0.67) | IRAK4ALDH1A1ACHEKCNK3KCNK9 | |
| SCHEMBL19537456 | 0.81 | IRAK4 (0.58) | IRAK4ALDH1A1ACHEKCNK3KCNK9 | |
| SCHEMBL19537451 | 0.81 | IRAK4 (0.58) | IRAK4ALDH1A1ACHEKCNK3KCNK9 | |
| SCHEMBL2094692 | 0.81 | IRAK4 (0.72) | IRAK4ALDH1A1ACHEKCNK3KCNK9 | |
| SCHEMBL7088362 | 0.81 | IRAK4 (0.72) | IRAK4ALDH1A1ACHEKCNK3KCNK9 | |
| SCHEMBL2646539 | 0.81 | KAT2B (0.57) | KCNK3KCNK9KAT2BBAZ2BGAA | |
| SCHEMBL4036585 | 0.80 | IRAK4 (0.66) | IRAK4ALDH1A1ACHEKCNK3KCNK9 | |
| SCHEMBL104892 | 0.79 | IRAK4 (0.70) | IRAK4ALDH1A1ACHEKCNK3KCNK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230130766-A1 | MONO AND COMBINATION THERAPIES WITH ULK1/2 INHIBITORS | SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2023-04-27 | — | — | US | disclosed |
| US-10774092-B2 | ULK1 inhibitors and methods using same | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190152989-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2019-05-23 | — | — | US | disclosed |
| US-20170312252-A1 | PYRROLIDINE AMIDE COMPOUNDS AS HISTONE DEMETHYLASE INHIBITORS | WUXI APPTEC (SHANGHAI) CO. LTD (CN) | 2017-11-02 | — | — | US | disclosed |
| US-20140243322-A1 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | COFERON, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243286-A1 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243321-A1 | BIOORTHOGONAL MONOMERS CAPABLE OF DIMERIZING AND TARGETING BROMODOMAINS, AND METHODS OF USING SAME | COFERON, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-8377921-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2013-02-19 | — | — | US | disclosed |
| US-8354403-B2 | Pyrrolidine derived beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243322-A1 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | BRDT, BRD2, BRD4 | IRAK4 2876/4885ALDH1A1 4558/4885ACHE 4033/4885 |
| US-20230130766-A1 | MONO AND COMBINATION THERAPIES WITH ULK1/2 INHIBITORS | ULK1, ULK2, ULK3 | IRAK4 796/4885ALDH1A1 3378/4885ACHE 4884/4885 |
| US-20140243286-A1 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | BRDT, BRD4, BRD1 | IRAK4 611/4885ALDH1A1 4589/4885ACHE 4675/4885 |
| US-20170312252-A1 | PYRROLIDINE AMIDE COMPOUNDS AS HISTONE DEMETHYLASE INHIBITORS | KDM5A, KDM5C, KDM5B | IRAK4 1479/4885ALDH1A1 1228/4885ACHE 3350/4885 |
| US-20190152989-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | ULK1, ULK2, ULK3 | IRAK4 1148/4885ALDH1A1 4167/4885ACHE 4859/4885 |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | IRAK4 1677/4885ALDH1A1 534/4885ACHE 1382/4885 |
| US-20140243321-A1 | BIOORTHOGONAL MONOMERS CAPABLE OF DIMERIZING AND TARGETING BROMODOMAINS, AND METHODS OF USING SAME | BRDT, BRD4, BRD1 | IRAK4 1633/4885ALDH1A1 4211/4885ACHE 4570/4885 |
| US-10774092-B2 | ULK1 inhibitors and methods using same | ULK1, ULK2, ULK3 | IRAK4 1136/4885ALDH1A1 4159/4885ACHE 4806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.